Newsletter Subject

Tirzepatide May Help Treat Sleep Apnea in People With Obesity

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Fri, Jun 21, 2024 10:47 PM

Email Preheader Text

Daily Headlines Friday, June 21, 2024 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT [N

[MEDPAGE TODAY]( Daily Headlines Friday, June 21, 2024 Today's Top Stories for {NAME} [MEETING COVERAGE]( [Tirzepatide May Help Treat Sleep Apnea in People With Obesity]( [PULMONOLOGY]( [Cannabis Use Tied to Increased Risk of Severe COVID]( [PRACTICE MANAGEMENT]( [Health Groups Have High Hopes for the Latest Prior Authorization Bill]( THE BREAK ROOM [Spell Check-Up: Try to Pass This Spelling Quiz]( CME SPOTLIGHT [Navigating the Nuances of von Hippel-Lindau (VHL) Disease Care: A Clinical Challenge in Treatment and Management]( [ONCOLOGY/HEMATOLOGY]( [Adagrasib Wins Accelerated Approval for KRAS-Mutant Colorectal Cancer]( [MEETING COVERAGE]( [Tech in Diabetes: What's Going Wrong?]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [ONCOLOGY/HEMATOLOGY]( [ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer]( CME SPOTLIGHT [Individualizing Advanced/Metastatic HER2+ Breast Cancer Care: Evidence-Based and Patient-Centered Approaches]( [ONCOLOGY/HEMATOLOGY]( [ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types]( [PUBLIC HEALTH & POLICY]( [FDA Authorizes First Menthol E-Cigarettes]( [ONCOLOGY/HEMATOLOGY]( [EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Optimizing Treatment With Infusion-Based Therapies for HR+/HER2- and Triple-Negative Breast Cancer]( [CARDIOLOGY]( [Cardiac Shockwave Device Passes Hurdle in Ischemic Cardiomyopathy]( [SPOTLIGHT ON]( [Beyond BCMA-Directed CAR T-Cell Therapy]( [PUBLIC HEALTH & POLICY]( [How Does Heat Kill? It Confuses the Brain, Shuts Down Organs, and Strains the Heart.]( CME SPOTLIGHT [Advancing the Application of the Latest Clinical Data in Secondary AML]( [GENETICS]( [Gene Therapy May Cure More Rare Diseases, but Drugmakers Have Few Incentives]( [PERSPECTIVES]( [Choosing a Primary Care Specialty Should Be Lauded, Not Discouraged]( [AAD READING ROOM]( [TNF-alpha Inhibitors and Lipid Profiles in Patients With Psoriasis]( CME SPOTLIGHT [Updates to AML Classification and Treatment Paradigm]( [PERSPECTIVES]( [Bullet-Related Injuries: 'The Problem Is Our Relationship to Lethal Force']( [MEETING COVERAGE]( [Subcutaneous Amivantamab Could Offer a Patient-Centered Approach to NSCLC Treatment]( [SPECIAL REPORTS]( [FDA Warns Yet Another Birth Tissue Company]( CME SPOTLIGHT [Applying the Latest Clinical Evidence to Treatment Plans for Pediatric Patients With Hodgkin Lymphoma]( [ASCO READING ROOM]( [The Swiftly Evolving Story of EGFR-Mutated NSCLC Management]( [NEUROLOGY]( [Gene Therapy for Duchenne Muscular Dystrophy Gets Expanded Approval]( # Weekly Survey [Should Congress Move on From COVID Origins?]( Accusations flew at a [Senate hearing]( on the origins of COVID-19 this week, but no conclusions were drawn -- as has been true for the House's pandemic subcommittee[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2024-06-21&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

26/06/2024

Sent On

26/06/2024

Sent On

26/06/2024

Sent On

25/06/2024

Sent On

25/06/2024

Sent On

24/06/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.